Full-Time

Sr. Scientist

Formulation Development

Confirmed live in the last 24 hours

Regeneron Pharmaceuticals

Regeneron Pharmaceuticals

10,001+ employees

Develops biopharmaceuticals for serious diseases

Compensation Overview

$108.3k - $176.7k/yr

Senior, Expert

Tarrytown, NY, USA

Category
Healthcare Administration & Support
Medical, Clinical & Veterinary
Requirements
  • PhD with 0-3 years experience or BS/MS with 8-10+ years experience
  • Hands-on experience in protein, antibodies and/or siRNA in a biopharmaceutical setting
  • Strong technical knowledge base
  • Proven experience with biophysical/biochemical characterization
  • Experience with bioanalytical method development
  • Troubleshooting proficiency with analytical and characterization techniques for biomolecules (such as column chromatographic (HPLC/UPLC), capillary electrophoresis and/or biophysical techniques (such as DLS, CD, FTIR, DSC, AUC) for protein characterization)
Responsibilities
  • Lead formulation and drug product development activities for multiple programs
  • Design and conduct biochemical and biophysical characterization and pre-formulation studies
  • Independently design and conduct stability studies and other experiments
  • Develop and apply analytical methods to support product characterization, formulation development, and stability testing
  • Serve as a program lead and subject matter expert at cross functional research, CMC and program teams
  • Conduct research (problem solving, characterizing protein stability, etc), present at external conferences and publish work
Desired Qualifications
  • Enjoy working in a highly collaborative setting
  • Excellent collaborative and communication skills
  • Demonstrated ability to multi-task to meet multiple deliverables
  • Experience in a variety of therapeutic modalities and approaches
Regeneron Pharmaceuticals

Regeneron Pharmaceuticals

View

Regeneron Pharmaceuticals develops medicines aimed at treating serious diseases such as cancer, eye diseases, and allergic conditions. The company uses its own technologies and extensive research to create new therapies, often collaborating with academic institutions and other pharmaceutical companies to enhance its efforts. Unlike many competitors, Regeneron focuses on both research and commercialization, generating revenue through the sale of its approved medicines and strategic partnerships. The goal of Regeneron is to improve patient outcomes by providing effective treatments and ensuring they meet safety and efficacy standards.

Company Size

10,001+

Company Stage

IPO

Headquarters

Town of Greenburgh, New York

Founded

1988

Simplify Jobs

Simplify's Take

What believers are saying

  • Acquisition of 23andMe assets enhances Regeneron's consumer genomics and drug discovery capabilities.
  • $3.6 billion Tarrytown expansion increases biologic medicine manufacturing capacity and efficiency.
  • FDA approval of Dupixent for CSU offers new treatment options, boosting market share.

What critics are saying

  • 23andMe acquisition may face delays due to bankruptcy court and regulatory approvals.
  • Tarrytown expansion's $3.6 billion cost could strain resources if not managed well.
  • AIM4 trial with Sanofi may encounter patient recruitment and execution challenges.

What makes Regeneron Pharmaceuticals unique

  • Regeneron leverages proprietary technologies for innovative drug discovery and development.
  • The company collaborates with academic and research institutions to enhance R&D efforts.
  • Regeneron focuses on personalized medicine, as seen in the AIM4 trial with Sanofi.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Wellness Program

Paid Vacation

Equity Awards

Annual Bonuses

Flexible Work Hours

Company News

Pharmaceutical Technology
May 20th, 2025
ATS 2025: Sanofi and Regeneron to launch new AIM4 trial for personalised asthma care

At the American Thoracic Society (ATS) 2025 Congress on 19 May, Sanofi and Regeneron announced the launch of a new Phase IIIb/IV clinical trial, AIM4, during an evening industry symposium.

Regeneron Pharmaceuticals
May 20th, 2025
Regeneron Enters into Asset Purchase Agreement to Acquire 23andMe® for $256 Million; Plans to Maintain Consumer Genetics Business and Advance Shared Goals of Improving Human Health and Wellness | Regeneron Pharmaceuticals Inc.

Purchase is subject to bankruptcy court and regulatory approvals Regeneron will prioritize the privacy, security and ethical use of 23andMe’s customer data; stands ready to work with independent, court-appointed Customer Privacy Ombudsman Planned purchase to strengthen Regeneron’s ongoing

BioPharmaTrend
May 19th, 2025
Regeneron Acquires 23andMe Assets for $256M to Expand Consumer Genomics and Data-Driven Drug Discovery

Regeneron acquires 23andMe assets for $256M to expand consumer genomics and data-driven drug discovery.

Hit Consultant
May 19th, 2025
Regeneron To Acquire Key 23Andme Assets For $256M, Pledges Continuity Of Consumer Genome Services

What You Should Know: – Regeneron Pharmaceuticals, Inc. announced it has been named the successful bidder in the bankruptcy auction for substantially all of the assets of 23andMe Holding Co. – Regeneron plans to acquire 23andMe’s Personal Genome Service® (PGS), Total Health and Research Services business lines, along with its extensive Biobank and associated assets, for $256 million.– Under the terms of the proposed acquisition, Regeneron intends for 23andMe to continue all its consumer genome services uninterrupted. The transaction is subject to bankruptcy court and regulatory approvals, as well as other customary closing conditions, and is anticipated to close in the third quarter of 2025.Strategic Move to Bolster Large-Scale Genetics ResearchRegeneron, a company with a long history of leveraging DNA insights for drug discovery, views this acquisition as a significant step in furthering its research capabilities. Regeneron, a company with a long history of leveraging DNA insights for drug discovery, views this acquisition as a significant step in furthering its research capabilities.“Regeneron was one of the first biotech companies to bet its future on the power of DNA, fueling our drug discovery efforts so as to deliver some of the world’s leading and most innovative medicines,” said George D. Yancopoulos, M.D. Ph.D., co-Founder, Board co-Chair, President and Chief Scientific Officer of Regeneron

PR Newswire
May 16th, 2025
75Th Annual Regeneron International Science And Engineering Fair Awards Teen Scientists From Around The World More Than $9 Million In 2025 Competition

Adam Kovalčík, 19, receives $100,000 Top Award for his development of a medicine that can stop viruses from copying genes and controlling infections at the world's largest pre-college STEM competition in Columbus, OhioTARRYTOWN, N.Y. and WASHINGTON, May 16, 2025 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. and Society for Science (the Society) announced that Adam Kovalčík, 19, of Dulovce, Slovakia, won the $100,000 George D. Yancopoulos Innovator Award at the 75th Regeneron International Science and Engineering Fair (Regeneron ISEF), the world's largest pre-college science and engineering competition. The award is named in honor of pioneering drug developer and Regeneron co-Founder, Board co-Chair, President and Chief Scientific Officer. Other top prizes went to projects in sustainable plastics engineering, air quality detection and advancement in prosthetics.Congratulations to the winners of the 2025 Regeneron International Science and Fair!The top winners were recognized during two award ceremonies: the Special Awards on May 15 and the Grand Awards Ceremony on May 16